Literature DB >> 20015790

Expression of the receptor activator for nuclear factor-κB ligand and osteoprotegerin in chronic otitis media.

Jerzy Kuczkowski1, Monika Sakowicz-Burkiewicz, Ewa Iżycka-Świeszewska.   

Abstract

BACKGROUND: The receptor activator for nuclear factor-κB ligand (RANKL) and osteoprotegerin (OPG) are the key factors controlling the osteoclast and osteoblast action in the bone.
PURPOSE: The study objective was to investigate the expression level of RANKL and OPG in cholesteatoma and granulation tissue, and to assess the relationship between their expression levels and osteolysis.
MATERIAL AND METHODS: Patients with chronic otitis media with cholesteatoma (n = 28) and without cholesteatoma (n = 24) treated surgically at the Department of Otolaryngology of the Medical University of Gdańsk were included in the study. RANKL and OPG expressions were analyzed by immunohistochemistry and Western blot.
RESULTS: RANKL and OPG were expressed in all cholesteatoma and granulation tissues. RANKL expression was mainly observed in cholesteatoma subepithelial stroma, whereas OPG-positive cells originated from the epithelium. The number of OPG-positive cells in the normal skin was significantly higher than in cholesteatoma tissues. The RANKL protein level in cholesteatoma tissues was 1.8- and 1.5-fold higher than in the auditory canal skin and granulation tissues, respectively. The number of RANKL-positive cells in cholesteatoma tissues was significantly higher than in the normal skin. No substantial differences were found in average OPG protein levels between cholesteatoma tissues and the normal auditory canal skin. The ratio of RANKL/OPG was significantly higher in cholesteatoma tissues (2.93 ± 0.79) than in the skin samples (1.36 ± 0.34).
CONCLUSIONS: Altered ratio of RANKL/OPG protein level in cholesteatoma tissues suggests that these proteins might be somehow involved in the pathogenesis of cholesteatoma. However, to resolve this issue a study on a larger group of patients should be conducted.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20015790     DOI: 10.1016/j.amjoto.2009.06.004

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  8 in total

Review 1.  The role of bone resorption in the etiopathogenesis of acquired middle ear cholesteatoma.

Authors:  Shumin Xie; Xiaoli Wang; Jihao Ren; Wei Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-12-16       Impact factor: 2.503

2.  Osteoclasts are not activated in middle ear cholesteatoma.

Authors:  Hiroki Koizumi; Hideaki Suzuki; Shoji Ikezaki; Toyoaki Ohbuchi; Koichi Hashida; Akinori Sakai
Journal:  J Bone Miner Metab       Date:  2015-03-22       Impact factor: 2.626

3.  The Association of IL-1 Alpha Level and TNF Alpha Expressions on Bone Destruction in Chronic Suppurative Otitis Media and Cholesteatoma.

Authors:  Bakti Surarto; Nyilo Purnami; Fransiska Hutahaen; M Reza Mahardhika
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2019-07-30

4.  Intercellular Communication between Keratinocytes and Fibroblasts Induces Local Osteoclast Differentiation: a Mechanism Underlying Cholesteatoma-Induced Bone Destruction.

Authors:  Yoriko Iwamoto; Keizo Nishikawa; Ryusuke Imai; Masayuki Furuya; Maki Uenaka; Yumi Ohta; Tetsuo Morihana; Saori Itoi-Ochi; Josef M Penninger; Ichiro Katayama; Hidenori Inohara; Masaru Ishii
Journal:  Mol Cell Biol       Date:  2016-05-16       Impact factor: 4.272

5.  Upregulation of phosphorylated HSP27, PRDX2, GRP75, GRP78 and GRP94 in acquired middle ear cholesteatoma growth.

Authors:  Kuen Yao Ho; Tai Sheng Yeh; Han Hsiang Huang; Kuo Feng Hung; Chee Yin Chai; Wan Tzu Chen; Shih Meng Tsai; Ning Chia Chang; Chen Yu Chien; Hsun Mo Wang; Yu Jen Wu
Journal:  Int J Mol Sci       Date:  2013-07-11       Impact factor: 5.923

6.  Why does the acquired cholesteatoma trigger resorption of the temporal bone?

Authors:  Jerzy Kuczkowski; Tomasz K Nowicki; Anna Starzyńska
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-14       Impact factor: 2.503

Review 7.  Review of potential medical treatments for middle ear cholesteatoma.

Authors:  Matthias Schürmann; Peter Goon; Holger Sudhoff
Journal:  Cell Commun Signal       Date:  2022-09-19       Impact factor: 7.525

8.  Incidence of Hip Fractures among Patients with Chronic Otitis Media: The Real-World Data.

Authors:  Pei-Shao Liao; Ching-Chih Chiu; Yi-Hsiu Fu; Chia-Chun Hsia; Yu-Cih Yang; Kun-Feng Lee; Shang-Lin Hsieh; Shu-Jui Kuo
Journal:  Medicina (Kaunas)       Date:  2022-08-22       Impact factor: 2.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.